बेल्जियम - डच - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

menarini international operations luxembourg s.a. - dexketoprofen trometamol 36,9 mg - eq. dexketoprofen 25 mg - filmomhulde tablet - dexketoprofen

नीदरलैंड - डच - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

medcor pharmaceuticals b.v. artemisweg 232 8239 de lelystad - mesalazine - maagsapresistent granulaat - aspartaam (e 951) ; carmellose natrium (e 466) ; cellulose, microkristallijn (e 460) ; citroenzuur 0-water (e 330) ; copolymeer van ethylacrylaat-methylmethacrylaat (2:1) ; copolymeer van methacrylzuur-methylmethacrylaat (1:1) ; dimeticon (e 900) ; hypromellose (e 464) ; magnesiumstearaat (e 470b) ; maltodextrine ; methylcellulose (e 461) ; nonoxinol ; povidon k 25 (e 1201) ; propyleenglycol (e 1520) ; saccharose ; siliciumdioxide (e 551) ; simeticon emulsie ; sorbinezuur (e 200) ; talk (e 553 b) ; titaandioxide (e 171) ; triethylcitraat (e 1505) ; vanilla custard flavour 75016-32 givaudan-roure

नीदरलैंड - डच - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

mesalazine 1000 mg/stuk - maagsapresistent granulaat - aspartaam (e 951) ; carmellose natrium (e 466) ; cellulose, microkristallijn (e 460(i)) ; citroenzuur 0-water (e 330) ; copolymeer van ethylacrylaat-methylmethacrylaat (2:1) (e 1206) ; copolymeer van methacrylzuur-methylmethacrylaat (1:1) ; dimeticon (e 900) ; hypromellose (e 464) ; magnesiumstearaat (e 470b) ; maltodextrine ; methylcellulose (e 461) ; nonoxinol ; povidon k 25 (e 1201) ; propyleenglycol (e 1520) ; saccharose ; siliciumdioxide (e 551) ; simeticon emulsie ; sorbinezuur (e 200) ; talk (e 553 b) ; titaandioxide (e 171) ; triethylcitraat (e 1505) ; vanilla custard flavour 75016-32 givaudan-roure, aspartaam (e 951) ; carmellose natrium (e 466) ; cellulose, microkristallijn (e 460) ; citroenzuur 0-water (e 330) ; copolymeer van ethylacrylaat-methylmethacrylaat (2:1) ; copolymeer van methacrylzuur-methylmethacrylaat (1:1) ; dimeticon (e 900) ; hypromellose (e 464) ; magnesiumstearaat (e 470b) ; maltodextrine ; methylcellulose (e 461) ; nonoxinol ; povidon k 25 (e 1201) ; propyleenglycol (e 1520) ; saccharose ; siliciumdioxide (e 551) ; simeticon emulsie ; sorbinezuur (e 200) ; talk (e 553 b) ; titaandioxide (e 171) ; triethylcitraat (e 1505) ; vanilla custard flavour 75016-32 givaudan-roure

नीदरलैंड - डच - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

mesalazine 1000 mg/stuk - maagsapresistent granulaat - aspartaam (e 951) ; carmellose natrium (e 466) ; cellulose, microkristallijn (e 460(i)) ; citroenzuur 0-water (e 330) ; copolymeer van ethylacrylaat-methylmethacrylaat (2:1) (e 1206) ; copolymeer van methacrylzuur-methylmethacrylaat (1:1) ; dimeticon (e 900) ; hypromellose (e 464) ; magnesiumstearaat (e 470b) ; maltodextrine ; methylcellulose (e 461) ; nonoxinol ; povidon k 25 (e 1201) ; propyleenglycol (e 1520) ; saccharose ; siliciumdioxide (e 551) ; simeticon emulsie ; sorbinezuur (e 200) ; talk (e 553 b) ; titaandioxide (e 171) ; triethylcitraat (e 1505) ; vanilla custard flavour 75016-32 givaudan-roure, aspartaam (e 951) ; carmellose natrium (e 466) ; cellulose, microkristallijn (e 460) ; citroenzuur 0-water (e 330) ; copolymeer van ethylacrylaat-methylmethacrylaat (2:1) ; copolymeer van methacrylzuur-methylmethacrylaat (1:1) ; dimeticon (e 900) ; hypromellose (e 464) ; magnesiumstearaat (e 470b) ; maltodextrine ; methylcellulose (e 461) ; nonoxinol ; povidon k 25 (e 1201) ; propyleenglycol (e 1520) ; saccharose ; siliciumdioxide (e 551) ; simeticon emulsie ; sorbinezuur (e 200) ; talk (e 553 b) ; titaandioxide (e 171) ; triethylcitraat (e 1505) ; vanilla custard flavour 75016-32 givaudan-roure

नीदरलैंड - डच - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

mesalazine mg/stuk - maagsapresistent granulaat - aspartaam (e 951) ; carmellose natrium (e 466) ; cellulose, microkristallijn (e 460(i)) ; citroenzuur 0-water (e 330) ; copolymeer van ethylacrylaat-methylmethacrylaat (2:1) (e 1206) ; copolymeer van methacrylzuur-methylmethacrylaat (1:1) ; dimeticon (e 900) ; hypromellose (e 464) ; magnesiumstearaat (e 470b) ; maltodextrine ; methylcellulose (e 461) ; nonoxinol ; povidon k 25 (e 1201) ; propyleenglycol (e 1520) ; saccharose ; siliciumdioxide (e 551) ; simeticon emulsie ; sorbinezuur (e 200) ; talk (e 553 b) ; titaandioxide (e 171) ; triethylcitraat (e 1505) ; vanilla custard flavour 75016-32 givaudan-roure, aspartaam (e 951) ; carmellose natrium (e 466) ; cellulose, microkristallijn (e 460) ; citroenzuur 0-water (e 330) ; copolymeer van ethylacrylaat-methylmethacrylaat (2:1) ; copolymeer van methacrylzuur-methylmethacrylaat (1:1) ; dimeticon (e 900) ; hypromellose (e 464) ; magnesiumstearaat (e 470b) ; maltodextrine ; methylcellulose (e 461) ; nonoxinol ; povidon k 25 (e 1201) ; propyleenglycol (e 1520) ; saccharose ; siliciumdioxide (e 551) ; simeticon emulsie ; sorbinezuur (e 200) ; talk (e 553 b) ; titaandioxide (e 171) ; triethylcitraat (e 1505) ; vanilla custard flavour 75016-32 givaudan-roure

नीदरलैंड - डच - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

huvepharma nv - tiamulinwaterstoffumaraat - granulaat - tiamulinwaterstoffumaraat 100 mg/g, - tiamulin - varkens

नीदरलैंड - डच - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

teva nederland b.v. swensweg 5 2031 ga haarlem - travoprost 40 µg/ml - oogdruppels, oplossing - benzalkoniumchloride ; boorzuur (e 284) ; dinatriumedetaat 2-water ; macrogolglycerolhydroxystearaat ; mannitol (d-) (e 421) ; natriumhydroxide (e 524) ; trometamol ; water voor injectie, - travoprost

नीदरलैंड - डच - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

huvepharma nv - florfenicol - granulaat voor gebruik in drinkwater - florfenicol 200 mg/g, - florfenicol - varkens

नीदरलैंड - डच - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

elanco gmbh - tiamulinwaterstoffumaraat - granulaat voor gebruik in drinkwater - tiamulinwaterstoffumaraat 450 mg/g, - tiamulin - kalkoenen; kippen; varkens

यूरोपीय संघ - डच - EMA (European Medicines Agency)

vertex pharmaceuticals (ireland) limited - ivacaftor - taaislijmziekte - andere producten van het ademhalingssysteem - kalydeco tablets are indicated:as monotherapy for the treatment of adults, adolescents, and children aged 6 years and older and weighing 25 kg or more with cystic fibrosis (cf) who have an r117h cftr mutation or one of the following gating (class iii) mutations in the cystic fibrosis transmembrane conductance regulator (cftr) gene: g551d, g1244e, g1349d, g178r, g551s, s1251n, s1255p, s549n or s549r (see sections 4. 4 en 5. in a combination regimen with tezacaftor/ivacaftor tablets for the treatment of adults, adolescents, and children aged 6 years and older with cystic fibrosis (cf) who are homozygous for the f508del mutation or who are heterozygous for the f508del mutation and have one of the following mutations in the cftr gene: p67l, r117c, l206w, r352q, a455e, d579g, 711+3a→g, s945l, s977f, r1070w, d1152h, 2789+5g→a, 3272 26a→g, and 3849+10kbc→t. in a combination regimen with ivacaftor/tezacaftor/elexacaftor tablets for the treatment of adults, adolescents, and children aged 6 years and older with cystic fibrosis (cf) who have at least one f508del mutation in the cftr gene (see section 5. kalydeco granules are indicated for the treatment of infants aged at least 4 months, toddlers and children weighing 5 kg to less than 25 kg with cystic fibrosis (cf) who have an r117h cftr mutation or one of the following gating (class iii) mutations in the cftr gene: g551d, g1244e, g1349d, g178r, g551s, s1251n, s1255p, s549n or s549r (see sections 4. 4 en 5. in a combination regimen with ivacaftor/tezacaftor/elexacaftor for the treatment of cystic fibrosis (cf) in paediatric patients aged 2 to less than 6 years who have at least one f508del mutation in the cftr gene.